Tags : Minor Acute Ischemic Stroke

AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THALES Study

Tuba Khan January 27, 2020

Shots: The P-III THALES study involves assessing of Brilinta (90mg, bid) + aspirin vs aspirin as monothx. in 11,000+ patients with minor acute ischemic stroke or high-risk TIA in the […]readmore

Tags : Minor Acute Ischemic Stroke

AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THALES Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Minor Acute Ischemic Stroke

AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THALES Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company